|
|
Post by vissertrades on Nov 25, 2015 10:01:21 GMT -5
What a freaking disaster this investment has been! $250,000 at a cost basis of $3.5, been invested since 2011. Nothing but dissapointment from MNKD. I will NEVER invest in biotech again.
|
|
|
|
Post by mssciguy on Nov 25, 2015 10:11:31 GMT -5
What a freaking disaster this investment has been! $250,000 at a cost basis of $3.5, been invested since 2011. Nothing but dissapointment from MNKD. I will NEVER invest in biotech again. You are right, the retail shareholder is almost completely disregarded here. However, the science and patent law is outstanding. Need a CEO who can 1. Get the website updated to the 21st century. It's basically very outdated html. 2. Summarize and present the patent portfolio. Highlight the most valuable elements. What will be acted upon first, and when? 3. Give investors something tangible. Will our warrants expire worthless? How can this happen? 4. Let more heads roll if someone is in the way of commercialization efforts. 5. Update retail investors weekly. Maybe a simple tweet. 6. Attract a variety of angel investors. There is no way Al Mann should carry all this weight on his own. If more personnel are required, great, but why not find them in universities? 7. All of the above should increase shareholder value, so that financing is no longer required at two bucks a share. It's an insult to long-term holders. |
|
|
|
Post by slugworth008 on Nov 25, 2015 10:16:16 GMT -5
Well said mssciguy. And I totally agree with your post.
|
|
|
|
Post by trondisc on Nov 25, 2015 10:20:27 GMT -5
Feels like the company is on life support when they shouldn't be for developing a revolutionary diabetes device. I'll be lucky to see mid single digits again maybe in 2016. I think MNKD needs multiple partnerships. SNY the sandbagger is suffocating MNKD's potential at world changing success.
|
|
|
|
Post by vissertrades on Nov 25, 2015 10:22:46 GMT -5
What a freaking disaster this investment has been! $250,000 at a cost basis of $3.5, been invested since 2011. Nothing but dissapointment from MNKD. I will NEVER invest in biotech again. You are right, the retail shareholder is almost completely disregarded here. However, the science and patent law is outstanding. Need a CEO who can 1. Get the website updated to the 21st century. It's basically very outdated html. 2. Summarize and present the patent portfolio. Highlight the most valuable elements. What will be acted upon first, and when? 3. Give investors something tangible. Will our warrants expire worthless? How can this happen? 4. Let more heads roll if someone is in the way of commercialization efforts. 5. Update retail investors weekly. Maybe a simple tweet. 6. Attract a variety of angel investors. There is no way Al Mann should carry all this weight on his own. If more personnel are required, great, but why not find them in universities? 7. All of the above should increase shareholder value, so that financing is no longer required at two bucks a share. It's an insult to long-term holders. And we now have a 90 year old Mann CEO! Seriously, push the life alert button - I've fallen and I can't get up! |
|
|
|
Post by mssciguy on Nov 25, 2015 10:29:09 GMT -5
vissertrades We'll have a new CEO sooner than later. Al has multiple companies to look after, he can't afford to spend all of his time on Mannkind. Company has ~300 employees. Just issue a list of demands, we gotta get this stuff done people.. who want's to volunteer. Low hanging fruit first. It's become a country club. No accountability to shareholders. Need an honest, competent, yet aggressive CEO. Have we been lied to during the past several months? Maybe. Honesty first.
|
|
|
|
Post by vissertrades on Nov 25, 2015 10:34:56 GMT -5
vissertrades We'll have a new CEO sooner than later. Al has multiple companies to look after, he can't afford to spend all of his time on Mannkind. Company has ~300 employees. Just issue a list of demands, we gotta get this stuff done people.. who want's to volunteer. Low hanging fruit first. It's become a country club. No accountability to shareholders. Need an honest, competent, yet aggressive CEO. Have we been lied to during the past several months? Maybe. Honesty first. He's 90 years old and juggling multiple companys, really? Tell me this is a joke! Haken sucked Mannkind dry and jumped with his golden parachute. BOD should be replaced too as this dysfunctional management is pathetic in whole! |
|
|
|
Post by kbrion77 on Nov 25, 2015 10:37:21 GMT -5
Feels like the company is on life support when they shouldn't be for developing a revolutionary diabetes device. I'll be lucky to see mid single digits again maybe in 2016. I think MNKD needs multiple partnerships. SNY the sandbagger is suffocating MNKD's potential at world changing success. This isn't your ordinary company nor your ordinary situation in my honest opinion. How long has this company been under attack for and why? Is there any other biotech story like this? You have how many hedge funds involved, hedge fund managers writing emails to the FDA and next thing you know they receive the CRL costing the company a billion, god knows how many competitors are involved to make this company and product fail. It really does feel like it's Mannkind vs. the World right now and it's super frustrating, not only for investors but the diabetic community as well. Hakan was operationally driven and from what it looks like he did a fine job to create the current manufacturing process but we need a CEO with vision and the you know what to go from our backs against the walls to on the offensive. |
|
|
|
Post by vissertrades on Nov 25, 2015 10:42:20 GMT -5
Agree, it's been war against Mannkind for some time. Who are the enemies that wants total destruction? Big Pharma, me thinks!
|
|
|
|
Post by mssciguy on Nov 25, 2015 10:58:47 GMT -5
Agree, it's been war against Mannkind for some time. Who are the enemies that wants total destruction? Big Pharma, me thinks! Well, that's part of business! It's always a fight. You can't make it as a publicly traded stock acting like a university. There are successful companies out there that do very well just developing intellectual property (great example is OLED -- but OLED develops intellectual property inside universities, not at a brand new facility in Connecticut and an old one in Southern Cal). Know your enemies and deal with them. Or, is that Sanofi's job? So many conflicts of interest and moral hazards here, life itself is too short to discuss them all. Happy Thanksgiving, forget all of noise. Nothing has changed, in fact Afrezza is ticking up in Rx and global exposure. Of course the stock price has bottomed out again in a multi-year cycle. Amazing, just amazing, though, that the current market cap is about what Shrekeli cost the company just a few years ago with his shorting and letters to FDA. Wow, just wow, as they say. Screaming buy, some might say, although that's little consolation to most of us. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 25, 2015 11:03:35 GMT -5
Big pharmaceuticals want to deep 6 MannKind. If this is not obvious to you, you are either delusional, naive or both.
|
|
|
|
Post by vissertrades on Nov 25, 2015 11:06:00 GMT -5
Inhaled tryptophan anyone? Cheers :-)
|
|
|
|
Post by ricguy on Nov 25, 2015 11:09:26 GMT -5
Agree, it's been war against Mannkind for some time. Who are the enemies that wants total destruction? Big Pharma, me thinks! Well, that's part of business! It's always a fight. You can't make it as a publicly traded stock acting like a university. There are successful companies out there that do very well just developing intellectual property (great example is OLED -- but OLED develops intellectual property inside universities, not at a brand new facility in Connecticut and an old one in Southern Cal). Know your enemies and deal with them. Or, is that Sanofi's job? So many conflicts of interest and moral hazards here, life itself is too short to discuss them all. Happy Thanksgiving, forget all of noise. Nothing has changed, in fact Afrezza is ticking up in Rx and global exposure. Of course the stock price has bottomed out again in a multi-year cycle. Amazing, just amazing, though, that the current market cap is about what Shrekeli cost the company just a few years ago with his shorting and letters to FDA. Wow, just wow, as they say. Screaming buy, some might say, although that's little consolation to most of us. Sleeping with the Enemy? :-) Someone should put a poll up as to what this website will look like in 2 years-the same, the url you reached is for sale, porn, spiro's hat sales, afeuerstein.com, lawyersforinvestors.com, hakansguideforceos.com, mnkdholicsanonymous.com, crowdfundingforbrokemnkdinvestors.com,howtomakemillionsoffofbiotechswhenitlookedliketheendandpeoplebailed.com fill in your own____, |
|
|
|
Post by mssciguy on Nov 25, 2015 11:14:38 GMT -5
ricguy, you are right, there is a big element of irrationality here, it's very high risk. High potential but the fundamentals and the chart are nauseating. Then again AAPL was the same way for many, many years. AMZN too.
|
|
|
|
Post by vissertrades on Nov 25, 2015 11:26:27 GMT -5
650,000 short available on IB new. Cover, reload, short, rinse and repeat! Hate this game.
|
|
